Your browser doesn't support javascript.
loading
Suicidality and Cannabidiol: Opportunities and Challenges.
Moazen-Zadeh, Ehsan; Galynker, Igor I.
Afiliación
  • Moazen-Zadeh E; Addiction Institute of Mount Sinai, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States.
  • Galynker II; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States.
Curr Neuropharmacol ; 19(6): 733-735, 2021.
Article en En | MEDLINE | ID: mdl-33059579
ABSTRACT
Cannabidiol (CBD) is gaining considerable attention in the research community with promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings for the therapeutic effects of CBD on psychotic and anxiety symptoms as well as substance use disorders, all of which are highly prevalent in patients who present with suicidality. Meanwhile, there has been a lack of suicide research on cannabidiol. This perspective provides an overview of the available evidence, potential reasons behind the halt in suicide research on cannabidiol, and recommendations for future investigations.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Suicidio / Cannabidiol / Trastornos Relacionados con Sustancias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Curr Neuropharmacol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Suicidio / Cannabidiol / Trastornos Relacionados con Sustancias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Curr Neuropharmacol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos